This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable
by Zacks Equity Research
Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
Zimmer Biomet (ZBH) Rides on ROSA Uptake, Favorable Trend
by Zacks Equity Research
Focused execution of Zimmer Biomet's (ZBH) global sales teams amid a stable global musculoskeletal market helps accelerate global sales.
Why Is Phibro (PAHC) Up 12.7% Since Last Earnings Report?
by Zacks Equity Research
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Labcorp (LH) Introduces Weight Loss Management Portfolio
by Zacks Equity Research
Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
by Zacks Equity Research
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
Alcon's (ALC) Vivity EDOF IOL Achieves One Million Milestone
by Zacks Equity Research
Alcon's (ALC) Vivity features the first-of-its-kind, patented wavefront-shaping technology, which simplifies presbyopia correction for surgeons and patients.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.
Abbott (ABT) to Reduce Childhood Malnutrition With New Pact
by Zacks Equity Research
Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.
Phibro (PAHC) Appears Well Poised on Launches, Vaccine Sales
by Zacks Equity Research
Phibro (PAHC) is focusing on new developments along with incremental registrations and growing volumes of existing nutritional specialties and vaccine technologies.
ResMed (RMD) Debuts the Smallest Full-Face CPAP Mask AirFit F40
by Zacks Equity Research
ResMed's (RMD) new AirFit F40 mask combines the ease and comfort of an ultra-compact, full-face mask with the effectiveness of a traditional over-the-nose, full-face mask.
Here's Why You Should Hold on to Neogen (NEOG) Stock Now
by Zacks Equity Research
Solid progress in long-term growth strategies bodes well for Neogen (NEOG).
Hologic's (HOLX) BCI Genomic Test Study Outcome Favorable
by Zacks Equity Research
Hologic's (HOLX) BCI test is the only genomic test that is approved by various national oncology guidelines.
Quanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
by Zacks Equity Research
Quanterix's (QTRX) blood-based biomarker test offers a non-invasive alternative, potentially revolutionizing how AD is diagnosed and managed.
Edwards (EW) Gains From RESILIA's Global Adoption, TAVR Growth
by Zacks Equity Research
With the Critical Care spin-off, Edwards (EW) is looking to pursue growth in TAVR, TMTT and Surgical, as well as new investments in interventional heart failure technologies.
Stryker (SYK) Completes First Arthroplasty Surgery in Europe
by Zacks Equity Research
Stryker (SYK) completes its first shoulder arthroplasty surgery in Europe using its Blueprint Mixed Reality Guidance system, which aims to benefit shoulder arthroplasty surgeons.
Haemonetics (HAE) Signs Agreement to Acquire Attune Medical
by Zacks Equity Research
Haemonetics' (HAE) acquisition of the privately held Attune Medical is likely to add the pioneering ensoETM device to its EP portfolio.
Reasons to Retain Prestige Consumer (PBH) Stock for Now
by Zacks Equity Research
Investors are optimistic about Prestige Consumer (PBH) on increasing gain in market share for its wide array of brands.
CVS Health (CVS) Expands In-Home Diagnostic Care With New Test
by Zacks Equity Research
CVS Health's (CVS) new launch will enable early detection of heart arrhythmia and can help mitigate symptoms and more severe complications.
Penumbra (PEN) Gains From Innovation, Mounting Costs Ail
by Zacks Equity Research
Penumbra (PEN) expects to materially increase both revenues and profitability in the company's international business in the next three years and beyond.
Here's Why Investors Should Retain Bruker (BRKR) Stock Now
by Zacks Equity Research
The strength of the BSI BioSpin and CALID groups bodes well for Bruker (BRKR).
QIAGEN (QGEN) Launches AI-Driven Biomedical Knowledge Base
by Zacks Equity Research
QIAGEN (QGEN) introduces a Biomedical KB-AI knowledge base to accelerate data-driven drug discovery.
Why Is Boston Scientific (BSX) Up 2.1% Since Last Earnings Report?
by Zacks Equity Research
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact
by Zacks Equity Research
Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) moving closer to achieving its vision of Autonomous Pharmacy.